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The search for biomarkers predicting 
metastasis-free survival or overall survival 
identified two key factors, namely estrogen 
receptor expression (Osborne et al., 1980) 
and the degree of proliferation (Gentili et 
al., 1981). However, a coherent picture did 
not emerge until the advent of gene array 
technology (Sørlie et al., 2001; Perou et al., 
2000; Rouzier et al., 2005; review: Schmidt 
et al., 2009a). Several groups have identi-
fied sets of genes that are associated with 
increased risk of metastasis (van’t Veer et 
al., 2002; Wang et al., 2005; van de Vijver 
et al., 2002; Foekens et al., 2006). It has 
become clear that these genes mostly repre-
sent proliferation, estrogen receptor alpha 
(ESR1) and immune cell associated genes 
(Paik et al., 2004; Sotiriou et al., 2006; Oh 
et al., 2006; Fan et al., 2006; Desmedt et al., 
2007; Schmidt et al., 2008). Two basic dis-
coveries have particularly contributed to the 
current knowledge on how gene expression 
relates to prognosis: 
 
• Perou and colleagues discovered that 
breast cancer is not a uniform disease. 
Instead, gene expression profiling dif-
ferentiates between five subtypes: lu-
minal A, luminal B, basal-like, normal-
like, and HER2-like (Perou et al., 
2000). All subtypes are meanwhile well 
established, and usually referred to as 
the ‘molecular subtypes of Perou’. 
• Schmidt and colleagues showed that 
three biological motifs are particularly 
important for breast cancer prognosis 
(Schmidt et al., 2008, 2009a). These 
motifs can be expressed as normalized 
means of gene sets and are usually ex-
pressed as the ’Schmidt metagenes’ of 
biological motifs. The first is the ‘pro-
liferation metagene’, which is associat-
ed with worse prognosis, particularly in 
estrogen receptor positive carcinomas. 
The second refers to the immune cell 
associated ‘B-cell’ and ‘T-cell’ meta-
genes that are associated with better 
prognosis, particularly in fast proliferat-
ing carcinomas. The third axis, the ‘es-
trogen receptor associated metagene’, is 
of limited prognostic relevance in node 
negative breast cancer, but is important 
when dissecting tumours according to 
biological processes. 
 
An important development made possi-
ble by the ’Schmidt metagenes’ is that the 
’Perou molecular subtypes’ are now better 
understood based on the underlying biolog-
ical processes. For example, ‘normal-like 
subtypes’ are characterized by low expres-
sion of the ‘proliferation metagene’ and 
high expression of the ‘estrogen receptor 
metagene’. ‘Luminal A subtypes’ express 
high estrogen receptor and high prolifera-
tion metagenes. The luminal B subtype dif-
fers from luminal A by having lower ex-
pression of the estrogen receptor but higher 
expression of the immune cell metagenes. 
Finally, ‘basal-like subtypes’ are HER2 
negative, with high expression of the prolif-
eration and immune cell metagenes, and 
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low expression of the estrogen receptor 
metagene. Therefore, Schmidt and col-
leagues (2008, 2009a) provided the biologi-
cal explanations of the molecular breast 
cancer subtypes originally discovered by 
Perou et al. (2000). 
Since metagenes require the analysis of 
a set of genes, a process that is relatively 
labour intensive, individual markers have 
been identified with a similar prognostic 
power as the entire metagenes. An example 
is immunoglobulin kappa C, which as a 
single gene can replace the entire ‘B cell 
metagene’ (Schmidt et al., 2012). Recent 
studies have reported that the state of redox 
control (Cadenas et al., 2010), antiapoptotic 
capacity (Petry et al., 2010), mechanoac-
tivity of breast tumor cells (Martin et al., 
2012), glycerophospholipid profiles (Ca-
denas et al., 2011) and stem cell properties 
of breast carcinomas (Lee et al., 2010) are 
also accompanied by specific gene expres-
sion profiles. Recent statistical advances 
include survival models using preclustered 
gene sets as covariates (Kammers et al., 
2011), and the development of prognostic 
algorithms based on bimodally expressed 
genes that have large differences between 
the high and low expression groups (Hell-
wig et al., 2010).  
Despite the progress achieved in gene 
expression profiling, one important clinical 
question remains unresolved: Adjuvant 
chemotherapy has clearly improved surviv-
al in node-negative breast cancer. This led 
to clinical recommendations of adjuvant 
systemic therapy for all patients (Schmidt et 
al., 2009b; Goldhirsch et al., 2007). How-
ever, even without chemotherapy approxi-
mately two-thirds of patients survive 10 
years after surgery (Schmidt et al., 2009b; 
2011; Brase et al., 2010). This illustrates 
that a large number of patients receive un-
necessary chemotherapy with all the associ-
ated adverse effects and negative influences 
on their quality of life. Unfortunately, clini-
copathological risk classification algorithms 
lack the sensitivity and specificity to justify 
the clinical decision to omit chemotherapy 
(Schmidt et al., 2009b). Therefore, an im-
portant future milestone will be to improve 
long-term outcome prediction algorithms so 
that unnecessary chemotherapies are avoid-
ed. 
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